J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront

J&J is trying something new for prostate cancer.

Teaming up with Xencor, its Janssen subsidiary is looking to discover bispecific antibodies that grab CD28 on one end and an undisclosed prostate tumor target on the other. The upfront comes in at $50 million.